Demethylation of cancer/testis antigens and CpG ODN stimulation enhance dendritic cell and cytotoxic t lymphocyte function in a mouse mammary model

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Sun, Jun Zhong ^a   Gao, Lei ^a   Gao, Li ^a,b   Wang, Wei ^a,b   Du, Nan ^a   Yang, Juan ^c   Wan, Ling ^a   Liu, Fang ^a   Wang, Li Li ^a   Yu, Li ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^c No 535 Hospital of Chinese People's Liberation Army   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CANCER TESTIS ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GRANZYME B; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; PERFORIN; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; GRANZYME; OLIGODEOXYRIBONUCLEOTIDE; PEPTIDE; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DEMETHYLATION; DENDRITIC CELL; DNA METHYLATION; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BAGG ALBINO MOUSE; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG EFFECT; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PHENOTYPE; PROMOTER REGION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANZYMES; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; PEPTIDES; PERFORIN; PHENOTYPE; PROMOTER REGIONS, GENETIC; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84888878651     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/196894     Document Type: Article

References (23)

1. Risk M., Corman: J. M., The role of immunotherapy in prostate cancer: an overview of current approaches in development. Reviews in Urology 2009 11 1 16 27
2. Nagaraj S., Gupta K., Pisarev V., Kinarsky L., Sherman S., Kang L., Herber D. L., Schneck J., Gabrilovich D. I., Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nature Medicine 2007 13 7 828 835 2-s2.0-34447118098 10.1038/nm1609 (Pubitemid 47038194)
3. LeGuern C., Tolerogenic property of MHC class I and class II molecules: lessons from a gene therapy approach. Frontiers in Bioscience 2007 12 8 3133 3139 2-s2.0-34347221199 10.2741/2301
4. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D. M., CpG DNA as a vaccine adjuvant. Expert Review of Vaccines 2011 10 4 499 511 2-s2.0-79955124819 10.1586/erv.10.174
5. Hofmann O., Caballero O. L., Stevenson B. J., Chen Y.-T., Cohen T., Chua R., Maher C. A., Panji S., Schaefer U., Kruger A., Lehvaslaiho M., Carninci P., Hayashizaki Y., Jongeneel C. V., Simpson A. J. G., Old L. J., Hide W., Genome-wide analysis of cancer/testis gene expression. Proceedings of the National Academy of Sciences of the United States of America 2008 105 51 20422 20427 2-s2.0-58149505629 10.1073/pnas.0810777105
6. Rosenberg S. A., Dudley M. E., Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 2004 101 2 14639 14645 2-s2.0-5144226237 10.1073/pnas.0405730101 (Pubitemid 39346736)
7. Roychowdhury S., May K. F. Jr., Tzou K. S., Lin T., Bhatt D., Freud A. G., Guimond M., Ferketich A. K., Liu Y., Caligiuri M. A., Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Research 2004 64 21 8062 8067 2-s2.0-7444252881 10.1158/0008-5472.CAN-04-1860 (Pubitemid 39446944)
8. Nishida N., Nishimura T., Nagasaka T., Ikai I., Goel A., Boland C. R., Extensive methylation is associated with β -catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis. Cancer Research 2007 67 10 4586 4594 (Pubitemid 46910163)
9. Anderson R. B., Cianciolo G. J., Kennedy M. N., Pizzo S. V., 2-Macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism. Journal of Leukocyte Biology 2008 83 2 381 392 2-s2.0-38949202945 10.1189/jlb.0407236 (Pubitemid 351225619)
10. Guo Z. S., Hong J. A., Irvine K. R., Chen G. A., Spiess P. J., Liu Y., Zeng G., Wunderlich J. R., Nguyen D. M., Restifo N. P., Schrump D. S., De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Research 2006 66 2 1105 1113 2-s2.0-31544432509 10.1158/0008-5472.CAN-05-3020 (Pubitemid 43165979)
11. Yu L., Liu C., Vandeusen J., Becknell B., Dai Z., Wu Y.-Z., Raval A., Liu T.-H., Ding W., Mao C., Liu S., Smith L. T., Lee S., Rassenti L., Marcucci G., Byrd J., Caligiuri M. A., Plass C., Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nature Genetics 2005 37 3 265 274 2-s2.0-20144366960 10.1038/ng1521 (Pubitemid 41716253)
12. Lašt'ovička J., Budinský V., Špí šek R., Bartůňková J., Assessment of lymphocyte proliferation: CFSE kills dividing cells and modulates expression of activation markers. Cellular Immunology 2009 256 1-2 79 85 2-s2.0-61849111200 10.1016/j.cellimm.2009.01.007
13. Ueno N. T., Bartholomeusz C., Xia W., Anklesaria P., Bruckheimer E. M., Mebel E., Paul R., Li S., Yo G. H., Huang L., Hung M.-C., Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Research 2002 62 22 6712 6716 2-s2.0-0037112449 (Pubitemid 35364142)
14. Tanaka M., Obata T., Sasaki T., Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. European Journal of Cancer 1996 32 2 226 230 2-s2.0-0029996299 10.1016/0959-8049(95) 00500-5
15. Huang H. F., Chen Y. Z., Wu Y., Chen P., Purging of murine erythroblastic leukemia by ZnPcS2 P2-based-photodynamic therapy. Bone Marrow Transplantation 2006 37 2 213 217 2-s2.0-30944470078 10.1038/sj.bmt.1705216 (Pubitemid 43108815)
16. Miller A. M., Pisa P., Tumor escape mechanisms in prostate cancer. Cancer Immunology, Immunotherapy 2007 56 1 81 87 2-s2.0-33751363704 10.1007/s00262-005-0110-x (Pubitemid 44812449)
17. Rosenberg S. A., Overcoming obstacles to the effective immunotherapy of human cancer. Proceedings of the National Academy of Sciences of the United States of America 2008 105 35 12643 12644 2-s2.0-51349095229 10.1073/pnas.0806877105
18. Hackanson B., Guo Y., Lübbert M., The silence of the genes: epigenetic disturbances in haemotopoietic malignancies. Expert Opinion on Therapeutic Targets 2005 9 1 45 61 2-s2.0-14744306996 10.1517/14728222.9.1.45 (Pubitemid 40331196)
19. Hoffmann T. K., Nakano K., Elder E. M., Dworacki G., Finkelstein S. D., Appella E., Whiteside T. L., DeLeo A. B., Generation of T cells specific for the wild-type sequence p53264-272 peptide in cancer patients: implications for immunoselection of epitope loss variants. Journal of Immunology 2000 165 10 5938 5944 2-s2.0-0034669973
20. Bermudez-Brito M., Muñoz-Quezada S., Gomez-Llorente C., Matencio E., Bernal M. J., Romero F., Gil A., Human intestinal dendritic cells decrease cytokine release against salmonella infection in the presenceof Lactobacillus paracasei upon TLR activation. PLoS One 2012 7 8 e43197
21. Krieg A. M., Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008 27 2 161 167 2-s2.0-37849002321 10.1038/sj.onc.1210911
22. Perreau M., Welles H. C., Pellaton C., Gjoksi B., Potin L., Martin R., Harari A., Bett A., Casimiro D., Gall J., Barouch D. H., Kremer E. J., Pantaleo G., The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes. Journal of Virology 2012 86 11 6279 6285 10.1128/JVI.00123-12
23. Hersperger A. R., Martin J. N., Shin L. Y., Sheth P. M., Kovacs C. M., Cosma G. L., Makedonas G., Pereyra F., Walker B. D., Kaul R., Deeks S. G., Betts M. R., Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. Blood 2011 117 14 3799 3808 2-s2.0-79953815120 10.1182/blood-2010-12-322727